Volume

Search documents
X @Unipcs (aka 'Bonk Guy') 馃帓
Unipcs (aka 'Bonk Guy') 馃帓路 2025-07-09 05:54
#USELESS coin is now the third most traded on-chain token on the Solana blockchain!#FARTCOIN and $JLP are the only tokens with more volume than USELESS, and it has edged above $TRUMP and $BONK in on-chain volume over the last few hoursthe consistently impressive volume on USELESS coin continues to be reminiscent of what volume was like on breakout memecoins like $SHIB and $PEPE in their very early days before they exploded!Unipcs (aka 'Bonk Guy') 馃帓 (@theunipcs):#USELESS coin is also the fourth most traded t ...
X @Cointelegraph
Cointelegraph路 2025-07-09 01:00
Market Trends - Solana (SOL) futures trading volume on CME Group, a major regulated derivatives exchange, exceeded $4 billion [1]
Struggling Macy's Stock Flashing Bearish Signal
Schaeffers Investment Research路 2025-07-08 18:22
Retail stock Macy's Inc (NYSE:M) was last seen up 1.1% at $12.59, and running into several layers of resistance on the charts. The $12.60 level has kept a lid on gains for the last couple months, while overhead pressure at the 100-day moving average has moved in as well -- a trendline that has preceded downturns in the past.聽Per Schaeffer's Senior Quantitative Analyst Rocky White, the stock is within 0.75 of the 100-day moving average's 20-day average true range (ATR), after spending at least 80% of the las ...
X @Unipcs (aka 'Bonk Guy') 馃帓
Unipcs (aka 'Bonk Guy') 馃帓路 2025-07-08 13:12
USELESS coin volume is officially at ATH... and by a wide margin!#USELESS has recorded more trading volume today than when it hit ATH days agoit is also doing more volume than several top memecoins listed on major CEXs like Robinhood, Coinbase, and Binanceif there is one thing that is clear, it is that whales and smart money are aggressively loading up on this 'dip'as they say, 'volume precedes price'Unipcs (aka 'Bonk Guy') 馃帓 (@theunipcs):pullbacks on #USELESS coin have rarely exceeded ~35% since it started ...
X @Token Terminal 馃搳
Token Terminal 馃搳路 2025-07-08 12:19
RT Token Terminal 馃搳 (@tokenterminal)鉀擄笍馃搱 @Tether_to's USDT averages $1 trillion in monthly onchain transfer volume.Wild. https://t.co/K0UqeK90Ot ...
X @Token Terminal 馃搳
Token Terminal 馃搳路 2025-07-07 23:27
RT Token Terminal 馃搳 (@tokenterminal)馃弴 Which DEX is growing the fastest on a % basis?馃搨 Market sectors馃搨 Exchanges (DEX)馃搨 Metrics馃搨 Trading volumeAnswer: @AxiomExchange https://t.co/hHLqbFMkYK ...
X @Token Terminal 馃搳
Token Terminal 馃搳路 2025-07-07 23:18
鉀擄笍馃搱 @Tether_to's USDT averages $1 trillion in monthly onchain transfer volume.Wild. https://t.co/K0UqeK90Ot ...
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
ZACKS路 2025-07-07 14:31
Core Viewpoint - Johnson & Johnson's MedTech segment, which constitutes approximately 36% of total revenues, is experiencing growth driven by newly acquired cardiovascular businesses and new product uptake, but faces challenges in the Asia Pacific region, particularly in China due to government procurement programs and competitive pressures [1][2][4]. Group 1: MedTech Segment Performance - The MedTech segment's growth in Q2 is attributed to the acquisition of Abiomed and Shockwave, alongside the continued uptake of new products [2]. - Sales in China are negatively impacted by the volume-based procurement (VBP) program and an anticorruption campaign, with no expected improvement in 2025 [2]. - Competitive pressures are affecting growth in specific MedTech areas, such as PFA ablation catheters in U.S. electrophysiology [3]. Group 2: Future Outlook - Sales are anticipated to be higher in the second half of 2025 compared to the first half as the business overcomes challenging first-quarter comparisons and new products gain traction [4]. - Tariff-related costs are expected to negatively impact profits in the MedTech segment [4]. Group 3: Competitive Landscape - J&J's MedTech unit faces significant competition from major players like Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [4][5]. Group 4: Financial Performance and Valuation - J&J's shares have outperformed the industry with a year-to-date increase of 9.7%, compared to a 0.6% rise in the industry [6]. - The company's shares are reasonably priced, trading at a price/earnings ratio of 14.43, lower than the industry average of 14.99 and below its five-year mean of 15.73 [8]. - The Zacks Consensus Estimate for 2025 earnings has increased slightly from $10.60 to $10.62 per share over the past 30 days [10].
X @Cointelegraph
Cointelegraph路 2025-07-07 05:00
馃敟 LATEST: Polygon surpassed $100B in all-time trading volume on the Uniswap Protocol. https://t.co/AXiuLLYzO2 ...
X @Token Terminal 馃搳
Token Terminal 馃搳路 2025-07-06 17:46
RT Token Terminal 馃搳 (@tokenterminal)馃攣馃搱 Daily trading volume on @AxiomExchange is up by ~200% over the past week. https://t.co/0NcgoYsoVm ...